Taken at face value, the results would suggest that the three SGLT2 inhibitors are "virtually identical," according to ...

A higher risk of HF hospitalization was seen with dapagliflozin over empagliflozin, but one researcher urges caution.

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...